Advertisement

Topics

SCRI TISSUE TESTING REGISTRY

2014-08-27 03:19:45 | BioPortfolio

Summary

Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

Description

Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

This study will consist of a registry of patients who have agreed to allow their tissue sample(s) (even those taken prior to their participation in an SCRI-sponsored trial) to be used by the SCRI Oncology Research Consortium at some point in the future for testing and analysis of expression analysis and/or analysis of tumor markers. The registry will be contained in an electronic database, and will be sorted by disease indication. (Note: Patients will not be asked to return at a future date and have tissue samples collected; rather, SCRI will have the authorization to obtain pre-existing samples).

Study Design

Observational Model: Cohort

Conditions

Melanoma

Intervention

Tissue Registry Study

Location

Tennessee Oncology, PLLC
Nashville
Tennessee
United States
37023

Status

Recruiting

Source

Sarah Cannon Research Institute

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:19:45-0400

Clinical Trials [2092 Associated Clinical Trials listed on BioPortfolio]

The Impact of Melanoma and Drug Treatment in the Real World

An observational, non-interventional registry study to collect real-world data from people living with melanoma and its treatment, which will be available to researchers to further the kno...

A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma

The main purpose of this trial is to evaluate the safety, tolerability and adverse event profile of pembrolizumab in subjects who have high risk melanoma before and after their standard o...

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Bortezomib will enhance the activity of dacarbazine against melanoma and soft tissue sarcoma. Weekly administration of the combination will prove to be feasible and tolerable at an appropr...

The Identification of Novel Prognostic Markers in Melanoma

The purpose of this project is to analyze tumour tissue from a group of subjects with malignant melanoma, who have been treated at the Royal Marsden Hospital.

HF Tissue Registry

This is a registry study. This is an observational, non-randomized, open, long-term project to collect biological samples (e.g. tissue and blood samples) in addition to clinical informatio...

PubMed Articles [17267 Associated PubMed Articles listed on BioPortfolio]

Clinical Outcomes Following Pulmonary Metastasectomy for Melanoma: A Population-Based Study.

Resection of pulmonary metastases is an important treatment option for patients with oligometastatic melanoma. There is currently no published data available on population-level outcomes. Here we repo...

Methotrexate Exposure and Risk of Cutaneous Malignant Melanoma: Investigation of a Possible Dose-response Relationship.

Methotrexate treatment has been linked with an increased risk of melanoma. However, a possible dose-response relationship with respect to methotrexate exposure and melanoma has not been addressed. The...

A population-based registry study on relative survival from melanoma in Germany stratified by tumor thickness for each histological subtype.

Differences in melanoma relative survival (RS) between histologies were discussed to be mainly caused by tumor thickness.

Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA (ctDNA) in metastatic melanoma.

Circulating tumor DNA (ctDNA) may serve as a surrogate to tissue biopsy for non-invasive identification of mutations across multiple genetic loci and for disease monitoring in melanoma. In this study,...

Variation in daily ultraviolet light exposure and sun protection behaviours of melanoma survivors: an observational single-arm pilot study with a wearable sensor.

Melanoma survivors are at risk to develop another melanoma and the same patterns of sun exposure that caused the initial melanoma contribute to the risk for a second melanoma. Despite awareness of the...

Medical and Biotech [MESH] Definitions

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)

Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.

A cellular subtype of malignant melanoma. It is a pigmented lesion composed of melanocytes occurring on sun-exposed skin, usually the face and neck. The melanocytes are commonly multinucleated with a "starburst" appearance. It is considered by many to be the in situ phase of lentigo maligna melanoma.

Found in large amounts in the plasma and urine of patients with malignant melanoma. It is therefore used in the diagnosis of melanoma and for the detection of postoperative metastases. Cysteinyldopa is believed to be formed by the rapid enzymatic hydrolysis of 5-S-glutathionedopa found in melanin-producing cells.

More From BioPortfolio on "SCRI TISSUE TESTING REGISTRY"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...


Searches Linking to this Trial